Experience with the ACURATE neo and neo2 transcatheter aortic valves in Spain. The PRECISA (PRospective Evaluation Complementing Investigation with ACURATE devices) registry

Author:

Tébar Daniel1ORCID,Carrillo Xavier2,García del Blanco Bruno34,Gómez‐Hospital Joan Antoni45,Nombela Luis6ORCID,Molina Eduardo7,Galeote Guillermo1,Vilalta Victoria2,Serra‐García Vicenc3,Carol Guillem Muntané5,Jiménez‐Valero Santiago1,Fernandez‐Nofrerias Eduard2ORCID,Calabuig‐Goena Álvaro3ORCID,Jurado‐Román Alfonso1ORCID,Sánchez‐Recalde Ángel8,Fernández‐Velasco María49,Bosca Lisardo410ORCID,Moreno Raúl111ORCID

Affiliation:

1. Servicio de Cardiología Hospital Universitario La Paz IdiPAZ Spain

2. Hospital German Trias i Pujol Badalona Spain

3. Hospital Vall D'Hebron Barcelona Spain

4. CIBERCV Madrid Spain

5. Hospital de Bellvitge Barcelona Spain

6. Hospital Clinico San Carlos Madrid Spain

7. Hospital Virgen de las Nievees Granada Spain

8. Hospital Ramón y Cajal Madrid Spain

9. Fundación de Investigación Hospital La Paz (IdiPAZ) Madrid Spain

10. Instituto de Investigaciones Biomédicas Sols‐Morreale (CSIC‐UAM)

11. Universidad Autónoma de Madrid Madrid Spain

Abstract

AbstractBackgroundPrevious studies have documented a high rate of implantation success with the ACURATE neo2 valve, as well as a reduction in paravalvular leak (PVL) compared to its predecessor, the ACURATE neo. However, there are no studies that have reviewed and compared the long‐term clinical and hemodynamic outcomes of these patients.AimsThis study aimed to evaluate the results of the ACURATE neo transcatheter aortic valve in a real‐world context, and to compare the results of the outcomes of both generations of this device (ACURATE neo and ACURATE neo2), with a specific focus on procedural success, safety, and long‐term effectiveness.MethodsA prospective study including all consecutive patients treated with the ACURATE neo device in seven hospitals was conducted (Clinical Trials Identification Number: NCT03846557). The primary endpoint consisted of a composite of adverse events, including mortality, aortic insufficiency, and other procedural complications. As the second‐generation device (ACURATE neo2) replaced the ACURATE neo during the study period, hemodynamic and clinical results before admission, at 30 days, and at 1 year of follow‐up were compared between the two generations.ResultsA total of 296 patients underwent transcatheter aortic valve implantation with the ACURATE device, with 178 patients receiving the ACURATE neo and 118 patients receiving the ACURATE neo2. In the overall population, the absence of device success occurred in 14.5%. The primary reason for the absence of device success was the presence of para‐valvular regurgitation ≥ 2. There were no instances of coronary occlusions, valve embolization, annulus rupture, or procedural deaths. ACURATE neo2 was associated with a significantly higher device success rate (91.7% vs. 82%, p = 0.04), primarily due to a significantly lower rate of para‐valvular regurgitation, which remained significant at 1 year.ConclusionThe use of ACURATE neo and neo2 transcatheter aortic valves is associated with satisfactory clinical results and an extremely low rate of complications. The ACURATE neo2 enables a significantly higher device success rate, primarily attributed to a significant reduction in the rate of PVL.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3